Source Feed: The Globe and Mail
Author: Jennifer Yang
Publication Date: October 28, 2025 - 07:00
Excitement around Alzheimer’s treatment tempered by questions about efficacy, accessibility
October 28, 2025
Lecanemab is the first new treatment for Alzheimer’s disease to reach Canada in 20 years, and Health Canada’s recent authorization of the disease-modifying drug has understandably triggered hope and excitement.
But for some researchers and clinicians who treat the disease, the development also represents a complicated story – one where enthusiasm for a new and desperately needed drug is tempered by sobering realities around its efficacy, accessibility and impact on an already strained health care system.
Unpublished Newswire
The Habsburg family has chosen the scion of a storied Canadian dynasty as trustee for its fabled collection of jewels, recently revealed to be stashed in Quebec after being presumed missing for a century. Andrew Molson, a board member of the Molson Coors brewery and chairman of Avenir Global, a Montreal-based network of global communications firms, will be responsible for stewarding the 137-carat Florentine Diamond and an emerald watch worn by Marie Antoinette, among other treasures.
November 22, 2025 - 05:00 | Eric Andrew-Gee | The Globe and Mail
I believe that Ambassador Hoekstra is the one meddling in Canadian politics. Read More
November 22, 2025 - 04:04 | Nicole Feriancek | Ottawa Citizen
My name is Carrie. I am 28 years old. I have struggled with an opioid use disorder and have experienced homelessness on and off for several years. Read More
November 22, 2025 - 04:00 | Bruce Deachman | Ottawa Citizen
Comments
Be the first to comment